iRGD, a cyclic 9-mer (CRGDKGPDC) CendR peptide, sequentially engages αvβ3/β5 integrins and, after proteolytic exposure of CRGDK/R, neuropilin-1, opening tumor vessels and stroma for deep penetration of ADCs, nanoparticles, oncolytic viruses, and imaging probes. Enhances therapeutic efficacy in vitro/in vivo.
Usually ships within 24 hours.